CORRECT trial for regorafenib success in Colorectal Cancer

Positive results are announced from the Phase III CORRECT trial of regorafenib ,a multi kinase inhibitor,from Bayer Healthcare, for the treatment of Metastatic Colorectal Cancer in patients whose disease has progressed after standard therapies. The Data Monitoring Committee has halted the study and placebo patients were transferred to regorafenib therapy. The trial met its primary endpoint of statistically significantly improving overall survival. The study demonstrates that regorafenib increases overall survival in patients with heavily pretreated mCRC, an area of high unmet medical need.